Emre Bayhan

Emre Bayhan

Auto-generated profile, based on publicly available information

Emre Bayhan

Department of Infectious Diseases and Clinical Microbiology, Gebze Fatih State Hospital, Gebze, Kocaeli, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YGYakup Gezer
Yakup Gezer
MTMuhammet Rıdvan Tayşi
Muhammet Rıdvan Tayşi
ATArzu Tarakçı
Arzu Tarakçı
SASevil Alkan
Sevil Alkan
SKSelçuk Kaya
Selçuk Kaya
EÖEthem Ömeroğlu
Ethem Ömeroğlu
The coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic hepatitis B (CHB) may influence liver fibrosis, but the rel

3 September 2026 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
YÇYeliz Çiçek
Yeliz Çiçek
SKSafak Kaya
Safak Kaya
MÇMustafa Kemal Çelen
Mustafa Kemal Çelen
SBSEYİT ALİ BÜYÜKTUNA
SEYİT ALİ BÜYÜKTUNA
MÇMehmet Çelik
Mehmet Çelik
EYErcan Yenilmez
Ercan Yenilmez
Background: Socioeconomic disadvantage may influence the chronic hepatitis B (CHB) care continuum and the stage at which clinically relevant liver disease is recognised. However, evidence linking both individual- and area-level socioeconomic disadvantage to histologically assessed liver fibrosis in CHB remains limited. We examined whether socioeconomic disadvantage at the individual and area levels was associated with liver fibrosis severity in adults with CHB in Türkiye. Methods: In this nationwide multicentre observational study, adults with CHB who underwent liver biopsy in routine care between 1 January 2019 and 31 December 2024 across 24 centres in Türkiye were screened. Clinical and histopathological data were obtained retrospectively from medical records, while socioeconomic data were collected after biopsy through structured face-to-face interviews. Fibrosis was staged using the Ishak system. Individual socioeconomic indicators and province-level categories of the socioeconomic development index (SEDI) were examined. The primary analysis used ordinal logistic regression. Supportive analyses included multivariable logistic regression, 1:1 propensity score matching with conditional logistic regression, overlap weighting, likelihood-ratio tests for interaction, chi-square or Fisher’s exact tests, Kruskal–Wallis tests, and Wilcoxon rank-sum tests, with Benjamini–Hochberg adjustment for post-hoc comparisons. Results: The analytic cohort included 956 adults, of whom 53.7% were male. Mild fibrosis (Ishak 0–2) was present in 73.1%, moderate fibrosis (3–4) in 21.7%, and advanced fibrosis/cirrhosis (5–6) in 5.2%. In multivariable ordinal regression, higher fibrosis stage was associated with older age at biopsy (adjusted OR = 1.12 per 10-year increase, 95% CI : 1.02–1.24; P = 0.019), longer travel time to a centre capable of CHB follow-up (adjusted OR = 1.53 per category, 95% CI : 1.30–1.79; P < 0.001), longer duration of residence in the current place of residence (adjusted OR = 1.21 per 5-year increase, 95% CI : 1.03–1.42; P = 0.023), and lower residential socioeconomic development (adjusted OR = 1.97 per one-level decrease, 95% CI : 1.82–2.15; P < 0.001). In matched and overlap-weighted comparisons of SEDI 6 versus SEDI 1, the corresponding estimates were OR = 26.00 (95% CI : 8.21–82.37; P < 0.001) and OR = 24.75 (95% CI : 8.96–68.36; P < 0.001), respectively. Conclusions: Liver fibrosis severity in adults with CHB was associated more consistently with area-level socioeconomic disadvantage of the current place of residence than with birthplace socioeconomic context or most individual socioeconomic indicators. These findings support a social epidemiological interpretation in which place-based disadvantage may be more closely linked to fibrosis severity at clinical presentation, potentially through unequal access to timely follow-up and specialist assessment.

1 January 2025 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
EÇErcan Çil
Ercan Çil
GKGülistan Karadeniz
Gülistan Karadeniz
GÇGökhan Çoraplı
Gökhan Çoraplı
ATAyse Sahin Tutak
Ayse Sahin Tutak
EBEmre Bayhan
Emre Bayhan
HSHakan Sezgin Sayiner
Hakan Sezgin Sayiner
Objective: Our objective was to analyze the impact of previous infection with atypical pneumonia pathogens on mortality in COVID‐19 patients. Materials and Methods: We retrospectively studied complete blood count, procalcitonin, C‐reactive protein, D‐dimer, ferritin, biochemistry, antibody levels of atypical pneumonia pathogens, and COVID‐19 (SARS‐CoV‐2) reverse transcriptase‐polymerase chain reaction (PCR) test results in combined (pharyngeal + nasopharyngeal) swab specimens from the airways of patients admitted to the pandemic wards and intensive care units of Adıyaman Training and Research Hospital between 04/01/2020 and 12/31/2021. Patients with positive COVID‐19 PCR test results were included in the study. Results: The mean age of the 323 patients was 60.9 ± 18.5 years, and 58.8% were male. When comparing patients with positive and negative antibodies to atypical pneumonia pathogens, we found no differences in mean age, sex, place of hospitalization, length of hospital stay, need for intensive care, and mortality. However, CRP, D‐dimer, and ferritin were significantly higher in the group of patients with antibody positivity for atypical pneumonia pathogens ( p values 0.008, 0.004, and 0.004). According to the results of multivariate regression analysis in COVID‐19 patients with positive antibodies with respect to atypical pneumonia pathogens, a glucose level higher than 148.5, an AST level higher than 26.5, and a lymphocyte count lower than 0.54 were found to be the most important risk factors for mortality in these patients (OR = 2.2, 95% CI 1.1–4.3, and p = 0.048, OR = 3.0, 95% CI 1.2–7.2, and p = 0.015, and OR = 4.1, 95% CI 1.9–8.9, and p < 0.001, respectively). According to the results of multivariate regression analysis, no risk factors for mortality were identified in patients with COVID‐19 without positive antibodies against atypical pneumonia pathogens. Conclusion: We found no association between positivity of antibodies of atypical pneumonia pathogens and mortality in COVID‐19 patients. However, elevated glucose and AST levels and low lymphocyte count were found to be important risk factors for mortality in COVID‐19 patients with positive antibodies against atypical pneumonia pathogens.